0001209191-22-016050.txt : 20220303 0001209191-22-016050.hdr.sgml : 20220303 20220303211926 ACCESSION NUMBER: 0001209191-22-016050 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Konidaris Tasos CENTRAL INDEX KEY: 0001320982 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 22711845 MAIL ADDRESS: STREET 1: 103 JFK PARKWAY CITY: SHORT HILLS STATE: NJ ZIP: 07078 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-01 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001320982 Konidaris Tasos C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 0 1 0 0 Executive Vice President & CFO Class A Common Stock 2022-03-01 4 M 0 36197 A 123916 D Restricted Stock Units 2022-03-01 4 M 0 36197 0.00 D Class A Common Stock 36197 108591 D Restricted Stock Units 2022-03-03 4 A 0 181159 0.00 A Class A Common Stock 181159 181159 D Performance-Based Restricted Stock Units 2022-03-03 4 A 0 362318 0.00 A Class A Common Stock 362318 362318 D Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units vest in four equal annual installments beginning on March 3, 2023. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 181,159 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. /s/ Meredith Cook, Attorney-in-Fact 2022-03-03